307 related articles for article (PubMed ID: 21745451)
1. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
[TBL] [Abstract][Full Text] [Related]
2. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
3. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
[TBL] [Abstract][Full Text] [Related]
4. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
Miglino M; Santini G; Grasso R; Pietrasanta D; Clavio M; Pierri I; Canepa L; Nati S; Ballerini F; Varaldo R; Palmisano G; Gobbi M
Haematologica; 2001 Jul; 86(7):706-14. PubMed ID: 11454525
[TBL] [Abstract][Full Text] [Related]
6. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
7. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
[TBL] [Abstract][Full Text] [Related]
9. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma.
Cremer FW; Ehrbrecht E; Kiel K; Benner A; Hegenbart U; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2000 Oct; 26(8):851-8. PubMed ID: 11081384
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
14. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
Zhou A; Shi Y; Feng F; Lu S; He X; Han X
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
[TBL] [Abstract][Full Text] [Related]
15. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
17. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]